Vernaglione 2003.

Methods	Study design: prospective RCT Time frame: NR Follow‐up period: 6 months
Participants	Country: Italy Setting: single centre Inclusion criteria: serum CRP levels ≥ 3 mg/L (42.2% of the entire population) undergoing HD treatment for at least 6 months, had patent autologous vascular access, and treated with the same dialyser in the last 3 months Number (treatment/control): 16/17 Age (mean ± SD) years: treatment group (65.2 ± 11.8); control group (65.5 ± 10.2) Sex (M/F): treatment group (4/12); control group (8/9) Exclusion criteria: patients with liver diseases, neoplasms, recent surgical interventions or trauma, sepsis, chronic inflammatory diseases, and those who had received prolonged treatments with NSAIDs and/or steroids and/or vitamins E or C
Interventions	Treatment group Atorvastatin Dose: 10 mg/d Treatment duration: 6 months Control group Placebo
Outcomes	Lipid parameters (TC, LDL, HDL, TG) Serum CRP Serum albumin Serum urea, SCr Adverse events: Serum ALT, AST, glutamyltransferase, CK, lactate dehydrogenase
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	NR
Allocation concealment (selection bias)	Unclear risk	NR
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	NR
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	NR
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	NR
Selective reporting (reporting bias)	High risk	Published reports did not include all expected outcomes
ITT analysis	Unclear risk	NR